You are here

faricimab

Roche grabs FDA okay for would-be blockbuster eye drug faricimab

Pharmaforum

Mon, 01/31/22 - 10:51 am

7 drugs likely to hit $1B in annual revenue in the next 5 years

Beckers Hospital Review

Thu, 01/13/22 - 07:31 am

Mirati Therapeutics

Go or no go? Roche’s fresh start for a new year

EP Vantage

Mon, 12/20/21 - 10:59 am

From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year

Fierce Pharma

Mon, 09/13/21 - 11:38 pm

FDA starts review of Roche’s eye disease drug, setting up 2022 verdict

Pharmaforum

Thu, 07/29/21 - 10:57 pm

bispecific antibodies

diabetic macular edema

wet age-related macular degeneration

Genentech Could Regain the Blindness-Related Disease Market with New Treatment

BioSpace

Sat, 02/13/21 - 11:01 pm

clinical trials

age-related macular degeneration

Roche eyes FDA filing after bispecific matches Eylea again

Fierce Biotech

Mon, 01/25/21 - 10:44 am

clinical trials

wet age-related macular degeneration

Roche eyes an uncertain market for faricimab

EP Vantage

Tue, 12/22/20 - 10:49 am

diabetic macular edema

Roche's bispecific matches Regeneron's Eylea in phase 3 trials

Fierce Biotech

Mon, 12/21/20 - 11:02 am

diabetic macular edema

clinical trials

bispecific antibodies

Roche flashes new 16-week bispecific AMD data, setting eyes on pair of PhIII trials

Endpoints

Wed, 05/6/20 - 12:17 pm

clinical trials

bispecific antibodies

wet age-related macular degeneration

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

Endpoints

Mon, 10/29/18 - 10:27 am